Trimelamol (N2,N4,N6-trihydroxymethyl -N2,N4,N6-trimethylmelamine) was developed as an analogue of hexamethylmelamine (HMM) which could be administered parenterally and which does not require metabolic activation (Rutty & Connors, 1977; Rutty & Abel, 1980) . This process is known to be relatively inefficient in man and may account for the poor clinical activity of pentamethylmelamine (PMM) (Rutty et al., 1982) . In phase I clinical trials Trimelamol proved less emetic and less neurotoxic than PMM, as predicted by preclinical studies (Judson et al., 1986) , and showed activity in patients with refractory ovarian cancer previously treated with platinum complexes (Judson et al., 1989) . Two in Table III . In the case of patients with pelvic masses or para-aortic nodes response was assessed by computerised tomography. A laparotomy was not performed to document pathological complete remission in the single patient with a complete response on radiological criteria. The patient with skin nodules had no other assessible disease, but did have a pleural effusion, ascites and a degree of bilateral hydronephrosis. The skin nodules disappeared completely, the effusion diminished and the hydronephrosis was unchanged. The patient's appetite and food intake improved for the duration of the response.
The previous response and treatment-free interval was examined in relation to response to Trimelamol. Only six patients (14%) were treated in first relapse, five following a previous complete response, one after a partial response, and none of these patients responded to Trimelamol. The median treatment-free interval for the six patients treated after a previous complete response was 14 months (range 6-18 months), but only exceeded 12 months in four cases. An additional six patients were treated after a previous partial response with a median treatment-free interval of 5 months (range 3-8). A total of 28 patients (66.6%) had previously proved refractory to chemotherapy prior to receiving Trimelamol or had progressive disease on treatment at the time of entry into the study. In this group the median treatmentfree interval was only 3 months (range 1-31). Only four patients in the whole group has a treatment-free interval in excess of 15 months.
Discussion
The response rate of 9.5% was disappointing in comparision with the activity observed in the phase I trial. In that study there was an objective response rate of 21.4% in patients treated at a dose of 1800 mg m2 or above, either by single or three daily doses. However, this difference in response rates was not statistically significant. It is of course difficult to draw firm conclusions from a phase I study because of potential bias in patient selection, however, the patient characteristics appeared similar in the two studies as was the myelosuppression observed. In both studies most patients had stage III or IV disease at initial presentation and a median performance status of 1. The median age was similar in both groups (57 vs 55) as was the extent of prior chemotherapy. Susceptibility to myelosuppression was equivalent given that the median WBC nadir was 3.0 x 109 I-l (0.8-6 .2) at 800 mg m2 daily x 3 in the phase I trial and 3.8 x 109 1' (1.0-11.2) in the phase II.
The likelihood of response to investigate agents in ovarian cancer has been shown to relate to the treatment-free interval (Blackledge et al., 1989) . A similar finding has been reported by Gore et al. (1990) in relation to rechallenge with platinum complexes. When these criteria are applied to the patients in this study it is clear that this was not a favourable group. Using the model reported by Blackledge et al. only 18 patients (43%) had a > 10% chance of responding and only four patients (9.5%) fell into the good prognosis group with a treatment-free interval> 15 months.
It may be relevant that three of the five responses observed on the fractionated dose schedule in phase I were seen at the higher doses of 900 or 1000 mg m-2 daily x 3 and myelosuppression in phase II was minor. Hence it is possible that the choice of dosage was too cautious for a drug with only limited activity in this difficult group of patients. Further dose escalation would have been difficult because of nausea and vomiting, but this might prove amenable to 5HT3 antagonists (Cunningham et al., 1987; Bermudez et al., 1988) .
In conclusion, Trimelamol at this dosage cannot be recommended for the treatment of patients with advanced ovarian cancer who have failed previous treatment with platinum complexes or have only a short treatment-free interval. Nevertheless the drug has some activity in this disease and its role remains to be defined. Bruckner et al. (1987) have claimed that patients with advanced ovarian cancer treated with combination chemotherapy including HMM have a prolonged survival. Evaluation of new agents in pre-treated patients is a major problem in this and other diseases and it may be premature to dismiss Trimelamol without further study in patients with a higher probability of response. At present formulation problems preclude further clinical studies.
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